OKYO Pharma (NASDAQ: OKYO) — Perfil da empresa, notícias e dados financeiros
OKYO Pharma focuses on innovative treatments for eye diseases, particularly dry eye and chronic ocular pain.
OKYO Pharma
OKYO Pharma ADR (NASDAQ:OKYO) is a biopharmaceutical company focused on developing innovative treatments to combat eye diseases, particularly those causing significant discomfort and vision impairment. Its pipeline of projects revolves around novel therapeutic peptides and small molecules aimed at addressing unmet needs in ophthalmology, with a keen emphasis on dry eye disease and chronic pain in ocular surfaces. OKYO Pharma's objective is to advance these cutting-edge therapies from the research stage through clinical trials, with the aim of eventually bringing new solutions to patients suffering from these debilitating conditions. The company is dedicated to improving quality of life through scientific breakthroughs and rigorous testing of their potential medications.
Resumo
Operações
Produtos e/ou serviços de OKYO Pharma
- Development of novel therapeutics for ocular diseases focusing on dry eye disease.
- Advancement of a proprietary GPCR agonist for treating ocular pain and inflammation.
- Researching non-opioid, receptor-targeted therapeutics for chronic pain management.
- Exploration of innovative treatments for age-related macular degeneration (AMD).
- Investigation into novel drug delivery systems for enhanced ocular drug bioavailability.
- Collaboration on biomedical research projects to identify potential new drug candidates for various diseases.
equipe executiva do OKYO Pharma
- Robert J. DempseyCEO & Executive Director
- Keeren ShahChief Financial Officer
- Rajkumar PatilChief Scientific Officer
- Gary S. JacobChief Development Officer & Director
- Flavio MantelliChief Medical Officer
- Michael Paul BeckFounder
Últimas notícias sobre a OKYO Pharma
OKYO Pharma secures positive FDA alignment for Phase 3 trial
United StatesOKYO Pharma reports quality-of-life breakthrough for urcosimod in nerve pain trial
United StatesOKYO Pharma’s nerve-repairing eye drop reaches first patient via FDA compassionate use
United StatesOKYO Pharma reports exploratory Phase 2 data for urcosimod in neuropathic corneal pain
United States
Principais indicadores financeiros
Resultados divulgados pela OKYO Pharma , em USD.
- Cap. de mercado
- 78,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -8,5 mi | -8,9 mi | |
| 0 | -7,2 mi | -4,7 mi | |
| 0 | -15,7 mi | -16,8 mi | |
| 0 | -13,1 mi | -13,3 mi |